NOVN Novan Inc.

0.78
+0.13  (+20%)
Previous Close 0.65
Open 0.75
Price To Book 3.92
Market Cap 20412602
Shares 26,069,734
Volume 63,983
Short Ratio
Av. Daily Volume 44,842

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released November 29, 2016. Primary endpoint met.
SB206
Human papillomavirus (HPV)
Phase 2 data released April 12, 2017. Primary endpoint met.
SB208
Fungal infections
Phase 3 top-line data released January 27, 2017. Met one of three co-primary endpoints in NI-AC301 trial. Met all endpoints in NI-AC302 trial. Additional Phase 3 trial required.
SB204
Acne vulgaris
Phase 3 trial to be initiated 2Q 2019 with data due late 2019 or 1Q 2020.
SB206
Molluscum contagiosum skin infection
Phase 1b trial completion announced August 20, 2018.
SB414
Atopic Dermatitis

Latest News

  1. Novan stock plummets as Durham company searches for additional financing
  2. Will NOVAN INC (NOVN) Report Negative Q4 Earnings? What You Should Know
  3. Novan and Sato Advance Japan Market and Dermatology Partnership
  4. Novan Completes End-of-Phase 2 Meeting and Provides Additional Business Updates
  5. Is WisdomTree International High Dividend Fund (DTH) a Strong ETF Right Now?
  6. Novartis Cosentyx® shows superior improvements in psoriasis patients' quality of life versus Janssen's IL-23 Stelara®*
  7. Novartis data confirm rapid response and high efficacy of Cosentyx® in psoriasis patients for first time in China
  8. Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
  9. Novartis issues summary financial information for the Alcon eye care business ahead of shareholder vote on proposed spin-off
  10. Novartis to pursue transformational therapy to reduce risk of cardiovascular disease in people living with elevated levels of inherited lipoprotein(a)
  11. Novartis receives FDA approval for Egaten® for the treatment of fascioliasis, a neglected tropical disease
  12. Novan Provides Business Update
  13. Novan faces delisting from Nasdaq
  14. Cramer's Exec Cut: The biggest names in health—and Apple—...
  15. Novartis CEO on chasing cures over profitable treatments
  16. Novan shakes up leadership again
  17. Novan Announces Management Changes and Provides Business Update
  18. Stocks down in December for pharma firms in the Triangle